HY-P990251 Search Results


lebrikizumab  (MedChemExpress)
93
MedChemExpress lebrikizumab
a , Barplot showing the effect of recombinant factors on the relative viability (normalized to untreated control) of L1236 cells at three days under low serum conditions; mean ± s.d. is depicted (n = 3); P < 0.05 is considered significant; two-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test. b , waterfall plots (ordered by increasing CRISPR gene effect score) showing genetic dependencies of 3 cHL cell lines (L1236, UHO1, L428). c, d . scatterplot of IL4R and IL13RA1 (c) and IL4R and STAT6 (d) gene effect scores across the DepMap dataset. e , effect of CRISPR/Cas9-mediated knock out of IL13RA1 or IL4R on L1236 cell viability (viable cell counts). f , rainplot of IL13 expression showing that the cHL cell lines (L1236, L428, and UHO1) show outlier expression of IL13. g , effect of CRISPR/Cas9-mediated knock out of IL13 on L1236 cell viability (viable cell counts), with or without recombinant IL13 supplementation (rIL13). h , dose-response analysis of tralokinumab, <t>lebrikizumab,</t> and dupilumab on L1236 cells. IC 50 values (95% confidence interval) are indicated on the right (n = 2); mean ± s.d. is depicted. The relative viability values represent the mean of two independent experimental replicates. i , time course analysis of the effect of tralokinumab, lebrikizumab, dupilumab (0.5 µM each), and isotype control antibody on L1236 cell viability (n = 3); mean ± s.d. is depicted. The C max range of these antibodies reported in clinical trials is indicated in grey. j , schematic representation of the proposed model of spatial organization and interactions that mediate tumor cell growth within the intact cHL tumor microenvironment. The data in e, g, and i are representative of three independent experiments.
Lebrikizumab, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lebrikizumab/product/MedChemExpress
Average 93 stars, based on 1 article reviews
lebrikizumab - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


a , Barplot showing the effect of recombinant factors on the relative viability (normalized to untreated control) of L1236 cells at three days under low serum conditions; mean ± s.d. is depicted (n = 3); P < 0.05 is considered significant; two-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test. b , waterfall plots (ordered by increasing CRISPR gene effect score) showing genetic dependencies of 3 cHL cell lines (L1236, UHO1, L428). c, d . scatterplot of IL4R and IL13RA1 (c) and IL4R and STAT6 (d) gene effect scores across the DepMap dataset. e , effect of CRISPR/Cas9-mediated knock out of IL13RA1 or IL4R on L1236 cell viability (viable cell counts). f , rainplot of IL13 expression showing that the cHL cell lines (L1236, L428, and UHO1) show outlier expression of IL13. g , effect of CRISPR/Cas9-mediated knock out of IL13 on L1236 cell viability (viable cell counts), with or without recombinant IL13 supplementation (rIL13). h , dose-response analysis of tralokinumab, lebrikizumab, and dupilumab on L1236 cells. IC 50 values (95% confidence interval) are indicated on the right (n = 2); mean ± s.d. is depicted. The relative viability values represent the mean of two independent experimental replicates. i , time course analysis of the effect of tralokinumab, lebrikizumab, dupilumab (0.5 µM each), and isotype control antibody on L1236 cell viability (n = 3); mean ± s.d. is depicted. The C max range of these antibodies reported in clinical trials is indicated in grey. j , schematic representation of the proposed model of spatial organization and interactions that mediate tumor cell growth within the intact cHL tumor microenvironment. The data in e, g, and i are representative of three independent experiments.

Journal: bioRxiv

Article Title: Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors

doi: 10.1101/2025.01.24.631210

Figure Lengend Snippet: a , Barplot showing the effect of recombinant factors on the relative viability (normalized to untreated control) of L1236 cells at three days under low serum conditions; mean ± s.d. is depicted (n = 3); P < 0.05 is considered significant; two-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test. b , waterfall plots (ordered by increasing CRISPR gene effect score) showing genetic dependencies of 3 cHL cell lines (L1236, UHO1, L428). c, d . scatterplot of IL4R and IL13RA1 (c) and IL4R and STAT6 (d) gene effect scores across the DepMap dataset. e , effect of CRISPR/Cas9-mediated knock out of IL13RA1 or IL4R on L1236 cell viability (viable cell counts). f , rainplot of IL13 expression showing that the cHL cell lines (L1236, L428, and UHO1) show outlier expression of IL13. g , effect of CRISPR/Cas9-mediated knock out of IL13 on L1236 cell viability (viable cell counts), with or without recombinant IL13 supplementation (rIL13). h , dose-response analysis of tralokinumab, lebrikizumab, and dupilumab on L1236 cells. IC 50 values (95% confidence interval) are indicated on the right (n = 2); mean ± s.d. is depicted. The relative viability values represent the mean of two independent experimental replicates. i , time course analysis of the effect of tralokinumab, lebrikizumab, dupilumab (0.5 µM each), and isotype control antibody on L1236 cell viability (n = 3); mean ± s.d. is depicted. The C max range of these antibodies reported in clinical trials is indicated in grey. j , schematic representation of the proposed model of spatial organization and interactions that mediate tumor cell growth within the intact cHL tumor microenvironment. The data in e, g, and i are representative of three independent experiments.

Article Snippet: For these experiments, the following three antibodies were used: Tralokinumab (MedChemExpress HY-P99053), Dupilumab (Selleck Chemicals A2038-1mg), and Lebrikizumab (MedChemExpress HY-P99025).

Techniques: Recombinant, Control, Comparison, CRISPR, Knock-Out, Expressing

a , Barplot showing the effect of recombinant factors on the relative viability (normalized to untreated control) of L1236 cells at three days at low-density growth conditions. b , barplot showing the effect of recombinant factors on the relative viability (normalized to untreated control) of UHO1 cells at three days grown under low serum conditions; for a and b, mean ± s.d. is depicted (n = 3). P < 0.05 is considered significant; two-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test. c , mean nuclear CellEvent Caspase 3/7 green fluorescence in IL4R and IL13RA1 knockout L1236 cells relative to intergenic control (24 hours after transduction/selection, n = 3) and representative composite images of the intergenic control and IL13RA1 knockout cells (channels: blue - DAPI, green – CellEvent green, transmitted light). d , the effect of withdrawing recombinant IL13 from IL13 knockout L1236 cells that were cultured in the presence of recombinant IL13 for 8 days (from the experiment shown in main ); mean ± s.d. is depicted (n = 2). e , dose-response analysis of tralokinumab, dupilumab, and lebrikizumab on UHO1 HRS cells (n = 4); mean ± s.e.m. is depicted. The C max range of these antibodies reported in clinical trials is indicated in grey. f , mean nuclear CellEvent Caspase 3/7 green fluorescence of L1236 cells treated with 0.5 µM Dupilumab or Tralokinumab relative to isotype control antibody (24 hours after treatment, n = 3) and representative composite images of the isotype control and dupilumab treated cells (channels: blue - DAPI, green – CellEvent green, transmitted light); For c and f, mean ± s.d. is depicted, the data are representative of two independent experiments and P values are determined by two-tailed t-tests. * P < 0.05, ** P < 0.01, *** P < 0.001. All scale bars: 150 µm.

Journal: bioRxiv

Article Title: Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors

doi: 10.1101/2025.01.24.631210

Figure Lengend Snippet: a , Barplot showing the effect of recombinant factors on the relative viability (normalized to untreated control) of L1236 cells at three days at low-density growth conditions. b , barplot showing the effect of recombinant factors on the relative viability (normalized to untreated control) of UHO1 cells at three days grown under low serum conditions; for a and b, mean ± s.d. is depicted (n = 3). P < 0.05 is considered significant; two-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test. c , mean nuclear CellEvent Caspase 3/7 green fluorescence in IL4R and IL13RA1 knockout L1236 cells relative to intergenic control (24 hours after transduction/selection, n = 3) and representative composite images of the intergenic control and IL13RA1 knockout cells (channels: blue - DAPI, green – CellEvent green, transmitted light). d , the effect of withdrawing recombinant IL13 from IL13 knockout L1236 cells that were cultured in the presence of recombinant IL13 for 8 days (from the experiment shown in main ); mean ± s.d. is depicted (n = 2). e , dose-response analysis of tralokinumab, dupilumab, and lebrikizumab on UHO1 HRS cells (n = 4); mean ± s.e.m. is depicted. The C max range of these antibodies reported in clinical trials is indicated in grey. f , mean nuclear CellEvent Caspase 3/7 green fluorescence of L1236 cells treated with 0.5 µM Dupilumab or Tralokinumab relative to isotype control antibody (24 hours after treatment, n = 3) and representative composite images of the isotype control and dupilumab treated cells (channels: blue - DAPI, green – CellEvent green, transmitted light); For c and f, mean ± s.d. is depicted, the data are representative of two independent experiments and P values are determined by two-tailed t-tests. * P < 0.05, ** P < 0.01, *** P < 0.001. All scale bars: 150 µm.

Article Snippet: For these experiments, the following three antibodies were used: Tralokinumab (MedChemExpress HY-P99053), Dupilumab (Selleck Chemicals A2038-1mg), and Lebrikizumab (MedChemExpress HY-P99025).

Techniques: Recombinant, Control, Comparison, Fluorescence, Knock-Out, Transduction, Selection, Cell Culture, Two Tailed Test